Kinase Inhibitors in Preclinical Development – 2021
First cancer targeting tyrosine kinase inhibitor imatinib was approved to enter the market by the US Food and Drug Administration...
Pipeline
Kinase Inhibitors in Clinical Development – 2021
First cancer targeting tyrosine kinase inhibitor imatinib was approved to enter the market by the US Food and Drug Administration...
Pre-Clinical Stage Monoclonal Antibodies in Active Development – 2021
Monoclonal Antibody Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.
Clinical Stage Monoclonal Antibodies in Active Development – 2021
Monoclonal Antibody Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.